A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma

BACKGROUND: Up to 50% of patients with uveal melanoma develop metastases (MUM) with a poor prognosis and median overall survival of approximately 1 year. METHODS: This phase I study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the oral protein kinase C inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., Kapiteijn, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006169/
https://www.ncbi.nlm.nih.gov/pubmed/36624219
http://dx.doi.org/10.1038/s41416-022-02133-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006169/
https://www.ncbi.nlm.nih.gov/pubmed/36624219
http://dx.doi.org/10.1038/s41416-022-02133-6

Ejemplares similares